Navigation Links
AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
Date:11/15/2012

IRVINE, Calif., Nov. 15, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that it has received a Notice of Issuance for its patent application for Dissolution of Arterial Plaque.  This patent issuance is the first major step in the development of the Company's intellectual property involving lipid modulation and reduction.  This issuance culminates a major effort by the Company and its patent counsel in pursuit of a patent covering the use of hyodeoxycholic acid for atherosclerotic plaque lesions. 

"This patent issuance is a tremendous milestone for the Company," said AtheroNova CEO Thomas W. Gardner.  "We are very confident that this patent will support our development project for AHRO-001 as we move toward the next phase of entering human clinical trials.  The Company's partner, OOO CardioNova, has completed a similar intellectual property filing on behalf of AtheroNova in the Eurasian markets and they expect action on these filings to be moving forward in the near future."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain pharmacological compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova is developing, and seeks to eventually market AHRO-001, a product that has the potential to become a new standard of care for patients prone to atherosclerotic plaque accumulation.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnolog
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Names New Director
2. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
3. AtheroNova Releases 2011 Financial Results
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Announces a New Board Member
6. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Ceres Receives $3.5 million from USAID for Trait Stacks
9. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
10. Hertz Fellow, Grant I. Gillary, Receives Hertz Foundation-George Lerman Fellowship
11. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 26, 2014  ViveBio, LLC ... sample collection, stabilization and transportation, announced today that ... Procurement Services, LLC (LPS) of Knoxville, ... products in the United States ... class of ambient temperature dried biological specimen transport ...
(Date:8/26/2014)... Francisco, CA (PRWEB) August 26, 2014 ... reach USD 8,020.1 million by 2020, according to a ... for personalized medicine and theranostics, and the subsequent introduction ... key factors driving market growth over the next six ... and chronic diseases such as cancer, coupled with disease ...
(Date:8/26/2014)... Aug. 26, 2014 Trovagene, Inc. (NASDAQ: ... Dx Summit; Moving Assays to the Clinic ... Monitoring of Cell Free Tumor DNA in Urine." ... of its Precision Cancer Monitoring (PCM) platform and ... for the detection of tumor DNA mutations from ...
(Date:8/26/2014)... NEW YORK , Aug. 26, 2014  That,s ... life science markets, today announced the formation of a ... strategic content development. The expanded team will combine current ... messaging areas at That,s Nice. ... Strategic Content to lead the team. Tiene was previously ...
Breaking Biology Technology:ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4That's Nice Announces Expanded Offering For Strategic Content And Public Relations 2That's Nice Announces Expanded Offering For Strategic Content And Public Relations 3
... VENTURA, Calif., Dec. 12 VivoMetrics Inc., a ... the,appointment of Howard R. Baker to the position ... Paul Kennedy, who will remain with,the company in ... Baker joins VivoMetrics with over 28 years in ...
... Oral Iclaprim, "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic ... First Modules ... Arpida Ltd,(SWX: ARPN) announced today the enrolment and dosing of ... iclaprim in the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) ...
... for the First Time on 50 mg/Day Dose for PRISTIQ ... Treatment of ... a division of Wyeth (NYSE: WYE ), announces that ... serotonin-norepinephrine reuptake inhibitor (SNRI), showed,that adult patients who received a ...
Cached Biology Technology:VivoMetrics(R) Appoints Howard R. Baker as New President and Chief Executive Officer 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:8/25/2014)... that there are 133 active fires in the North Slave ... in the past 24 hours. Fire danger is moderate to ... , The Birch Lake Complex of fires are in an ... within 30 km north of Fort Providence. Four crews ... Moraine Point this week. Mop-up continues many areas of complex,s ...
(Date:8/25/2014)... The Happy Camp Complex of fires began as a lightning ... consumed 22,670 acres and is 20% contained. There ... present. It consists of many small fires and a ... have been contained and only account for about 100 acres. ... the morning and early afternoon on August 24, keeping fire ...
(Date:8/25/2014)... August 25, 2014 Nearly 1 in 6 adults ... time, the disorder can cause serious complications. Auriculotherapy, ... points on the outer ear, may help in ... between 2007-2013 that evaluated the effectiveness of auriculotherapy ... discussed in a Review article in The ...
Breaking Biology News(10 mins):Happy Camper and July Fire Complexes in California 2
... ANN ARBOR, Mich. The risk of esophageal cancer ... is not as high as many may think, according ... GERD is considered a relative risk for developing esophageal ... Joel Rubenstein, M.D., M.Sc., an investigator with the Department ...
... -- When their razor-sharp mandibles wear out, leaf-cutter ants ... sisters take over cutting, say researchers from two Oregon ... regular publication in the journal Behavioral Ecology and ... of providing for its displaced workers. "This ...
... can dive for anything up to 15 minutes. However, Bob ... blue whales may be able to dive for longer, because ... blood and muscles, so why don,t they? ,The theory was ... lot of energy, says Shadwick. Explaining that the whales feed ...
Cached Biology News:Esophageal cancer risk lower than expected for patients with GERD 2When their tools get dull, leaf-cutters switch jobs 2When their tools get dull, leaf-cutters switch jobs 3Blue whale-sized mouthfuls make foraging super efficient 2
... The Dodeca silver stain kits are ... devices including Bio-Rad Dodeca stainers. This ... quantities of proteins in polyacrylamide gels ... kit includes sensitizer concentrate, silver reagent ...
The AVR9-8 stream-select valve is a 9-port, 8-position valve for use with the BioLogic DuoFlow system. This valve is used for high-pressure stream selection....
... stain for staining RNA (bluish-purple), DNA (blue), proteins (red) ... ≥ 90 % Cation traces: Ca ≤ 10 mg/kg ... ≤ 5 mg/kg Cu ≤ 5 mg/kg Fe ≤ ... mg/kg Mn ≤ 5 mg/kg Na ≤ 50 mg/kg ...
... Biometras Tpersonal thermocycler provides maximum performance ... generation of Peltier elements, high heating and ... to short run times. With a maximum ... Tpersonal provides half the capacity of much ...
Biology Products: